pitolisant

Sponsor Harmony Biosciences Holdings, INC. · listed as HRMY

READOUT Phase 3 Confidence: medium Source: clinicaltrials

pitolisant is a clinical-stage drug asset sponsored by Harmony Biosciences Holdings, INC., listed as HRMY. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Jul 2026 (month precision, medium confidence), tied to trial NCT06366464. The asset is in Phase 3 and currently recruiting, studied in Prader-Willi Syndrome. It appears across 2 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT

Expected date2026-07-31

As disclosedJul 2026

Date precisionmonth

Confidencemedium

Verify at source →

Trial & sponsor

Trial (NCT)NCT06366464

PhasePHASE3

StatusRECRUITING

Lead sponsorHarmony Biosciences Management, Inc.

Listed asHRMY

Condition(s)Prader-Willi Syndrome

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 → More HRMY catalysts